Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10547-10554

  Lai, Hao ^a   Jin, Qinwen ^a   Lin, Yuan ^a   Mo, Xianwei ^a   Bo, Li ^a   Ke, He ^a   Chen, Jiansi ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Gastric cancer; Lysyl oxidase; Predictive value

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA-72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN LYSINE 6 OXIDASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BIOSYNTHESIS; BLOOD; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; STOMACH TUMOR;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AREA UNDER CURVE; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEIN-LYSINE 6-OXIDASE; ROC CURVE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922391630     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2355-5     Document Type: Article

References (41)

1. Thun MJ, DeLancey JO, Center MM, JemalA, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31: 100–10.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
3. Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, Yang K, et al. Costeffectiveness analysis of chemotherapy for advanced gastric cancer in china. World J Gastroenterol. 2008;14:2715–22.
4. Tan Z, Jiang H, Wu Y, Xie L, Dai W, Tang H, et al. Mir-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. Mol Cell Biochem. 2014;386:223–31.
5. Zeng Z, Wang J, Zhao L, Hu P, Zhang H, Tang X, et al. Potential role of microrna-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS ONE. 2013;8:e73278.
6. He CZ, Zhang KH. Serum protein and genetic tumor markers of gastric carcinoma. Asian Pac J Cancer Prev. 2013;14:3437–42.
7. Shi W, Yang B, Li X, Sun S, Wang L, Jiao S. The effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancer. Tumour Biol. 2012;33:2379–83.
8. Liu JL, Wei W, Tang W, Jiang Y, Yang HW, Li JT, et al. Silencing of lysyl oxidase gene expression by RNA interference suppresses metastasis of breast cancer. Asian Pac J Cancer Prev. 2012;13:3507–11.
9. Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z, et al. Hypoxia inducible factor 1alpha-mediated lox expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol. 2013;42:1578–88.
10. Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, et al. Loxl2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat. 2013;141:89–99.
11. Woznick AR, Braddock AL, Dulai M, Seymour ML, Callahan RE, Welsh RJ, et al. Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg. 2005;189:297–301.
12. Cox TR, Erler JT. Lysyl oxidase in colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2013;305:G659–66.
13. Hu WQ, Peng CW, Li Y. The expression and significance of pglycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. J Exp Clin Cancer Res. 2009;28:144.
14. Bian J, Li B, Kou XJ, Liu TZ, Ming L. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev. 2013;14:6241–3.
15. Wang Z, Tian YP. Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma. Mol Clin Oncol. 2014;2:265–8.
16. Yu T, Yu H, Cai X. Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19-9 and carcinoembryonic antigen. Chin Med J. 2014;127:2299–303.
17. Han H, Du B, Pan X, Liu J, Zhao Q, Lian X, et al. Cadpe inhibits pma-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Mol Cancer Res. 2010;8:1477–88.
18. Monig SP, Nolden B, Lubke T, Pohl A, Grass G, Schneider PM, et al. Clinical significance of nm23 gene expression in gastric cancer. Anticancer Res. 2007;27:3029–33.
19. Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18:3726–31.
20. Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:661–5.
21. Cidon EU, Cuenca IJ. Gastric adenocarcinoma: is computed tomography (CT) useful in preoperative staging? Clin Med Oncol. 2009;3: 91–7.
22. Seevaratnam R, Cardoso R, McGregor C, Lourenco L, Mahar A, Sutradhar R, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2012;15 Suppl 1:S3–S18.
23. Ozkan E, Araz M, Soydal C, Kucuk ON. The role of 18 FFDG-PET/CT in the preoperative staging and posttherapy follow up of gastric cancer: comparison with spiral CT. World J Surg Oncol. 2011;9:75.
24. Shalhav AL, Chan SW, Bercowsky E, Elbahnassy AM, McDougall EM, Clayman RV. Laparoscopic exploration in the management of retroperitoneal masses. JSLS. 1999;3:209–14.
25. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002;22: 2311–6.
26. Louhimo J, Finne P, Alfthan H, Stenman UH, Haglund C. Combination of HCGbeta, CA 19-9 and CEAwith logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res. 2002;22:1759–64.
27. Hwang GI, Yoo CH, Sohn BH, Shin JH, Park YL, Kim HD, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat. 2004;36:178–81.
28. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27–39.
29. Zhang Q, Jin XS, Yang ZY, Wei M, Zhu XC, Wang P, et al. Upregulated expression of lox is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncol Lett. 2013;5:896–902.
30. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron. 2012;5:261–73.
31. Abourbih DA, Di Cesare S, Orellana ME, Antecka E, Martins C, Petruccelli LA, et al. Lysyl oxidase expression and inhibition in uveal melanoma. Melanoma Res. 2010;20:97–106.
32. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154–61.
33. Chen XZ, Zhang WK, Yang K, Wang LL, Liu J, Wang L, et al. Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep. 2012;39:9031–9.
34. Spila A, Roselli M, Cosimelli M, Ferroni P, Cavaliere F, Arcuri R, et al. Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res. 1996;16:2241–7.
35. Mattar R, Alves DAC, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:89–92.
36. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncol-Basel. 1999;57:55–62.
37. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008;25:1075–84.
38. Aloe S, D’Alessandro R, Spila A, Ferroni P, Basili S, Palmirotta R, et al. Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. Int J Biol Markers. 2003;18:21–7.
39. Duraker N, Celik AN. The prognostic significance of preoperative serum ca 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76:266–71.
40. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, et al. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol. 1996;91:49–53.
41. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer association. Gastric Cancer. 2014;17:26–33.